{"id":12651,"date":"2025-01-27T14:42:57","date_gmt":"2025-01-27T19:42:57","guid":{"rendered":"https:\/\/transfusionontario.org\/?p=12651"},"modified":"2025-01-27T15:42:23","modified_gmt":"2025-01-27T20:42:23","slug":"multiple-sclerosis-relapsing-remitting-multiple-sclerosis-short-term-therapy-igum","status":"publish","type":"post","link":"https:\/\/transfusionontario.org\/en\/multiple-sclerosis-relapsing-remitting-multiple-sclerosis-short-term-therapy-igum\/","title":{"rendered":"Multiple Sclerosis (MS) &#8211; Relapsing remitting multiple sclerosis (RRMS), short-term therapy"},"content":{"rendered":"\n<p>(See separate entry for <a href=\"https:\/\/transfusionontario.org\/en\/multiple-sclerosis-igum\">MS<\/a>)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-color has-link-color has-medium-font-size wp-elements-036f609a813ebf7c494f7208c56cbbdc\" style=\"color:#477d6c\"><strong>Recommended Indications in which IG can be used<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading has-black-color has-text-color has-background has-link-color has-small-font-size wp-elements-23df72f37f149c5e7ca94c843ea1d320\" style=\"background-color:#a5cbbf\"><strong>Order Number: N7-RRMS<\/strong><span style=\"font-size: medium; font-weight: 400; white-space-collapse: collapse;\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table is-style-regular\"><table><tbody><tr><td><strong>Recommendations<\/strong><\/td><td>IVIG is recommended for short-term therapy in patients with clinically definite relapsing remitting MS, confirmed by a neurologist, and one of the following indications:<br><ol><li>Severe relapse of clinically definite RRMS with no response to high-dose methylprednisolone or where methylprednisolone is contraindicated.<\/li><li>Prevention of relapse of clinically definite RRMS where alternative therapies are inappropriate, unavailable, or contraindicated.<\/li><\/ol><span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/td><\/tr><tr><td><strong>Dose\/Frequency of Administration<\/strong><\/td><td><strong>Induction: <\/strong>1 to 2 g\/kg adjusted body weight divided over 1 to 5 days (maximum 1 g\/kg\/day).<br><br><strong>Maintenance (for indication 2):<\/strong> 0.4 to 1 g\/kg adjusted body weight every 4 to 6 weeks.<br><br>Once the patient\u2019s condition has stabilized, consider titrating the dose and\/or the treatment interval to the lowest dose necessary to maintain clinical effectiveness.<span style=\"font-size: medium; white-space-collapse: collapse;\"><\/span><\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Recommended Indications in which IG can be used<\/p>\n<p>Order Number: N7-RRMS<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"footnotes":""},"categories":[398],"tags":[],"class_list":["post-12651","post","type-post","status-publish","format-standard","hentry","category-neurology-indications"],"acf":[],"_links":{"self":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts\/12651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/comments?post=12651"}],"version-history":[{"count":0,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts\/12651\/revisions"}],"wp:attachment":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/media?parent=12651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/categories?post=12651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/tags?post=12651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}